Neuropharmacology
August 2001
M Spitzer, B Franke, H Walter et al.
In a randomised double-blind trial the subjective, neuropsychological and brain activation effects of the two enantiomers of the MDMA (ecstasy-) like drug N-ethyl-3,4-methylenedioxyamphetamine (MDE) were studied in five normal subjects using functional magnetic resonance imaging (fMRI). (S)-MDE produced elevated mood, impairments in conceptually driven cognition and marked right frontal...
European psychiatry : the journal of the Association of European Psychiatrists
December 1, 1998
Euphrosyne Gouzoulis‐mayfrank, Elmar Habermeyer, L Hermle et al.
Clinical evidence suggests that hallucinogenic drug-induced altered states of consciousness (ASCs) and the incipient, acute stages of endogenous psychoses share many common phenomenological features. The aim of our study was to assess hallucinogen-like phenomena in endogenous psychotic patients using standardised methods. We examined 93 endogenous psychotic patients, 50 healthy controls and a...
Pharmacopsychiatry
July 1998
Euphrosyne Gouzoulis‐mayfrank, L Hermle, B Thelen et al.
Systematic scientific interest in psychedelic substances has a tradition of about 100 years. Numerous human experimental studies have confirmed the existence of a common nucleus of experiences in hallucinogen-induced states and the acute stages of schizophrenic psychoses. However, the degree of resemblance between endogenous and drug-induced psychotic states has been an issue of controversial...
Fortschritte der Neurologie-Psychiatrie
December 1996
L Hermle, E Gouzoulis-Mayfrank, M Spitzer
The concepts of intoxication, intoxication psychosis, and drug-induced psychosis are frequently used to refer to psychopathological states caused by the intake of hallucinogenic substances. The considerable increase of intoxications with substances of the chemical class of amphetamines (in particular, "Ecstasy") in western countries should cause major concern. Moreover, the number of...
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
May 1993
E Gouzoulis, U Von Bardeleben, A Rupp et al.
The drug 3,4-methylenedioxyethamphetamine ([MDE] also known as "Eve") is a less toxic analog of 3,4-methylenedioxymethamphetamine (also known as "Ecstasy") with similar psychotropic effects in humans. In a double-blind placebo-controlled, cross-over study we administered 140 mg of MDE or placebo orally to eight healthy male volunteers at 1:30 P.M. Serum cortisol, prolactin (PRL), and growth...
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
February 1993
L Hermle, M Spitzer, D Borchardt et al.
The so-called entactogens 3,4-methylenedioxymethamphetamine ([MDMA] also known as "Ecstasy," or "Adam") and its analog 3,4-methylenedioxyethamphetamine ([MDE] also known as "Eve") exert similar psychotropic effects in humans. Two double-blind placebo-controlled psychometric studies with normal control subjects were conducted. Placebo or MDE (140 mg) was administered orally to eight male...